Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 19 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACELL from Wortegem-Petegem, company number BE0738956985, closed financial year 2025 with a result of € 223,035 after tax. For that financial year PHARMACELL recorded a gross margin of € 224,405 and equity of € 494,200. Compared with financial year 2024, the result moved from € 184,776 to € 223,035. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ 494,200
▼ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 223,035
▲ 21% vs 2024
Profit after tax over the fiscal year.
€ 62,484
▼ 4% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 604,584 paid out
More than the year’s profit went to the shareholders; reserves fell.
Debts at end 2025
€ 511,108
▼ 19% vs 2024
€ 121,194 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 1,902
▲ € 1,699 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 29,132
▲ 74% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 145,242 | € 164,572 | € 250,342 | € 224,405 | ▼ 10% |
| Profit after taxes | € 100,046 | € 129,762 | € 184,776 | € 223,035 | ▲ 21% |
| Equity | € 591,211 | € 720,973 | € 875,749 | € 494,200 | ▼ 44% |
| Total debts | € 916,285 | € 766,102 | € 678,608 | € 1,089,039 | ▲ 60% |
| Cash | € 71,491 | € 43,979 | € 65,333 | € 62,484 | ▼ 4% |
| Retained profit | € 291,211 | € 420,973 | € 575,749 | € 194,200 | ▼ 66% |
| Dividend | € 0 | € 0 | € 30,000 | € 604,584 | ▲ € 574,584 |
| Bank debt | € 869,210 | € 750,749 | € 631,384 | € 511,108 | ▼ 19% |
| Balance sheet total | € 1,507,496 | € 1,487,075 | € 1,554,357 | € 1,583,239 | ▲ 2% |
Key figures of PHARMACELL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACELL?
What happened at PHARMACELL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 223,035 (▲ 21% vs 2024). Source: NBB ↗
- New establishment in Wortegem-Petegem. KBO
- Start of the company according to the CBE. KBO
- Ellen De Stoop became a director. NBB
In short
From € 100,046 profit in 2022 to € 223,035 profit in 2025.
Paid € 182,946 in corporate taxes since 2022.
Best year ever: 2025, with € 223,035 profit.
Paid out € 634,584 in dividends to the owners in total.
Management
Behind PHARMACELL is Ellen De Stoop. It owns 100% of Apotheek De Stoop Deinze itself.
Directors
According to the 2025 annual accounts
since 2019
Establishments
Establishment units
Physical locations of this company
Wortegemplein (W.) 9 box 1
9790 Wortegem-Petegem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.956.985
- VAT number
- BE 0738.956.985
- Registered office
- Wortegemplein (W.) 9 bus 1, 9790 Wortegem-Petegem
- Names & denominations
- PHARMACELL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 December 2019
- Peppol
- Active · Active since 13 May 2025
- Activities · NACE
Activiteiten van holdings
Holdings